# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Guggenheim analyst Evan Wang reiterates CureVac (NASDAQ:CVAC) with a Neutral.
CureVac reveals Phase 2 interim data for its seasonal influenza vaccine in collaboration with GSK. Results show broad antigen c...
CureVac N.V. (NASDAQ:CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines b...
-SEC Filing
CureVac N.V. (NASDAQ: CVAC) shares are trading higher on Friday.
Shares of Compugen Ltd. (NASDAQ: CGEN) shares rose sharply during Tuesday’s session after Gilead announced an agreement with t...
A German court has invalidated a patent central to CureVac N.V's (NASDAQ: CVAC) lawsuit against BioNTech SE (NASDAQ: BNTX) ...